Cargando…

Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers

Parkinson’s disease (PD) is currently the world’s fastest-growing neurological disorder. It is characterized by motor and non-motor symptoms which progressively lead to significant clinical impairment, causing a high burden of disease. In addition to pharmacological therapies, various non-pharmacolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Daniel, Bartig, Dirk, Muhlack, Siegfried, Hartelt, Elke, Scherbaum, Raphael, Katsanos, Aristeides H., Müller, Thomas, Jost, Wolfgang, Ebersbach, Georg, Gold, Ralf, Krogias, Christos, Tönges, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406830/
https://www.ncbi.nlm.nih.gov/pubmed/30754730
http://dx.doi.org/10.3390/cells8020151
_version_ 1783401414309969920
author Richter, Daniel
Bartig, Dirk
Muhlack, Siegfried
Hartelt, Elke
Scherbaum, Raphael
Katsanos, Aristeides H.
Müller, Thomas
Jost, Wolfgang
Ebersbach, Georg
Gold, Ralf
Krogias, Christos
Tönges, Lars
author_facet Richter, Daniel
Bartig, Dirk
Muhlack, Siegfried
Hartelt, Elke
Scherbaum, Raphael
Katsanos, Aristeides H.
Müller, Thomas
Jost, Wolfgang
Ebersbach, Georg
Gold, Ralf
Krogias, Christos
Tönges, Lars
author_sort Richter, Daniel
collection PubMed
description Parkinson’s disease (PD) is currently the world’s fastest-growing neurological disorder. It is characterized by motor and non-motor symptoms which progressively lead to significant clinical impairment, causing a high burden of disease. In addition to pharmacological therapies, various non-pharmacological treatment options are available. A well established and frequently used multiprofessional inpatient treatment concept in Germany is “Parkinson’s disease multimodal complex treatment” (PD-MCT) which involves physiotherapists, occupational therapists, speech therapists, and other specializations for the optimization of treatment in PD (ICD G20) and other Parkinsonian syndromes (ICD G21 and G23). In this study we analyze the PD-MCT characteristics of 55,141 PD inpatients who have been integrated into this therapy concept in Germany in the years 2010–2016. We demonstrate that PD-MCT is increasingly applied over this time period. Predominately, PD patients with advanced disease stage and motor fluctuations in age groups between 45 and 69 years were hospitalized. In terms of gender, more male than female patients were treated. PD-MCT is provided primarily in specialized hospitals with high patient numbers but a minor part of all therapies is performed in a rather large number of hospitals with each one treating only a few patients. Access to PD-MCT differs widely across regions, leading to significant migration of patients from underserved areas to PD-MCT centers–a development that should be considered when implementing such therapies in other countries. Furthermore, our data imply that despite the overall increase in PD-MCT treatments during the observational period, the restricted treatment accessibility may not adequately satisfy current patient’s need.
format Online
Article
Text
id pubmed-6406830
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64068302019-03-19 Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers Richter, Daniel Bartig, Dirk Muhlack, Siegfried Hartelt, Elke Scherbaum, Raphael Katsanos, Aristeides H. Müller, Thomas Jost, Wolfgang Ebersbach, Georg Gold, Ralf Krogias, Christos Tönges, Lars Cells Article Parkinson’s disease (PD) is currently the world’s fastest-growing neurological disorder. It is characterized by motor and non-motor symptoms which progressively lead to significant clinical impairment, causing a high burden of disease. In addition to pharmacological therapies, various non-pharmacological treatment options are available. A well established and frequently used multiprofessional inpatient treatment concept in Germany is “Parkinson’s disease multimodal complex treatment” (PD-MCT) which involves physiotherapists, occupational therapists, speech therapists, and other specializations for the optimization of treatment in PD (ICD G20) and other Parkinsonian syndromes (ICD G21 and G23). In this study we analyze the PD-MCT characteristics of 55,141 PD inpatients who have been integrated into this therapy concept in Germany in the years 2010–2016. We demonstrate that PD-MCT is increasingly applied over this time period. Predominately, PD patients with advanced disease stage and motor fluctuations in age groups between 45 and 69 years were hospitalized. In terms of gender, more male than female patients were treated. PD-MCT is provided primarily in specialized hospitals with high patient numbers but a minor part of all therapies is performed in a rather large number of hospitals with each one treating only a few patients. Access to PD-MCT differs widely across regions, leading to significant migration of patients from underserved areas to PD-MCT centers–a development that should be considered when implementing such therapies in other countries. Furthermore, our data imply that despite the overall increase in PD-MCT treatments during the observational period, the restricted treatment accessibility may not adequately satisfy current patient’s need. MDPI 2019-02-11 /pmc/articles/PMC6406830/ /pubmed/30754730 http://dx.doi.org/10.3390/cells8020151 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Richter, Daniel
Bartig, Dirk
Muhlack, Siegfried
Hartelt, Elke
Scherbaum, Raphael
Katsanos, Aristeides H.
Müller, Thomas
Jost, Wolfgang
Ebersbach, Georg
Gold, Ralf
Krogias, Christos
Tönges, Lars
Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
title Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
title_full Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
title_fullStr Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
title_full_unstemmed Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
title_short Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
title_sort dynamics of parkinson’s disease multimodal complex treatment in germany from 2010–2016: patient characteristics, access to treatment, and formation of regional centers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406830/
https://www.ncbi.nlm.nih.gov/pubmed/30754730
http://dx.doi.org/10.3390/cells8020151
work_keys_str_mv AT richterdaniel dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT bartigdirk dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT muhlacksiegfried dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT harteltelke dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT scherbaumraphael dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT katsanosaristeidesh dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT mullerthomas dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT jostwolfgang dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT ebersbachgeorg dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT goldralf dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT krogiaschristos dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters
AT tongeslars dynamicsofparkinsonsdiseasemultimodalcomplextreatmentingermanyfrom20102016patientcharacteristicsaccesstotreatmentandformationofregionalcenters